home / stock / vcnx / vcnx news

VCNX News and Press, Vaccinex Inc. From 12/10/19

Stock Information
Company Name: Vaccinex Inc.
Stock Symbol: VCNX
Market: NASDAQ
Website: vaccinex.com
Menu
VCNX VCNX Quote VCNX Short VCNX News VCNX Articles VCNX Message Board
Get VCNX Alerts

News, Short Squeeze, Breakout and More Instantly...
VCNX - Vaccinex Announces $3 Million Award from the Alzheimer's Drug Discovery Foundation

ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that it has been granted an award, in the form of an investment of up to app...
VCNX - Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer's Disease

ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and nuerodegenerative diseases, today announced that it presented the scientific rationale and design of its...

VCNX - Vaccinex Announces Award Notice from the Alzheimer's Association 2020 Part the Cloud Program

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ROCHESTER, N.Y., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), ...

VCNX - Vaccinex EPS beats by $0.10, beats on revenue

Vaccinex (NASDAQ: VCNX ): Q3 GAAP EPS of -$0.56 beats by $0.10 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VCNX - Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Mee...

VCNX - Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepine...

VCNX - Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board

GERMANTOWN, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Gl...
VCNX - Vaccinex's pepinemab shows encouraging action in treatment-resistant lung cancer

Updated data from a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating the combination of Vaccinex's (NASDAQ: VCNX ) lead candidate pepinemab and Pfizer (NYSE: PFE ) and Merck KGaA's  ( OTCPK:MKGAF ) Bavencio (avelumab) in patients with treatment-resistant advanced non-small cel...

VCNX - Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conferen

ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepin...

VCNX - Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference

ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive ...
Previous 10 Next 10